

ASX ANNOUNCEMENT

Benitec Biopharma's presentation at 6th Annual Pain Therapeutics Summit

San Jose, California, USA, October 3, 2012: Benitec Biopharma's Chief Scientist Dr Michael Graham today presented a scientific update on the progress of the Company's cancer-associated neuropathic pain program at the *6th Annual Pain Therapeutics Summit* in San Jose, California. The title of Dr Graham's presentation was: **Gene Therapy to Control Intractable Pain in Cancer Patients: A New Paradigm?**

Benitec Biopharma's ddRNAi-based program represents a novel approach to treatment of intractable cancer-associated pain, and it is being progressed under a contractual agreement with Stanford University.

The presentation indicates that the gene target, protein kinase C gamma (PRKCG), has been well validated as a key pain associated mediator, proof of concept has been obtained that silencing this gene in vivo produces effective pain relief in an animal model, and that experiments are underway with both scientists at TetraQ and Professor David Yeomans at Stanford University to validate new constructs which have been produced by our GMP manufacturer and that target regions on PRKCG which are conserved between human and other species. This validation is essential for the subsequent toxicology and biodistribution studies required by regulatory authorities prior to gaining approval for a clinical trial, which is targeted for 2013.

About Benitec Biopharma Limited

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), also called expressed RNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as cancer-associated pain, Hepatitis B, drug resistant lung cancer and OPMD based on this technology.

For more information please contact

Dr Peter French, Chief Executive Officer

Phone: +61 (02) 9555 6986

Email: pfrench@benitec.com